Lung Diseases Cies Search Engine [selected websites]

Blog Archive

Apr 16, 2008

AVEO’s Novel Triple VEGF Receptor Inhibitor... Clinical Activity and Tolerability in other Solid Tumors including Colon and Lung Cancers

April 14, 2008AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that their novel oral triple VEGF receptor inhibitor AV-951 shows clinical activity in multiple advanced solid tumor types including renal, colon and lung cancers and is well tolerated according to new data from the expanded Phase 1 clinical trial of the company’s lead product candidate. Partial response or stable disease was observed across all patients with renal cell carcinoma, and overall, one-third of patients across all tumor types achieved tumor shrinkage during treatment with AV-951... AVEO Pharmaceuticals' Press Release -